Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Selexipag - Actelion/Nippon Shinyaku

Next Previous
Search
Drug Profile

Selexipag - Actelion/Nippon Shinyaku

Alternative Names: ACT-293987; JNJ-678896049; NS-304; Uptravi

Latest Information Update: 10 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nippon Shinyaku
  • Developer Actelion Pharmaceuticals; Nippon Shinyaku
  • Class Acetamides; Amines; Anti-inflammatories; Antithrombotics; Pyrazines; Small molecules; Sulfonamides; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension; Pulmonary hypertension
  • Phase III Arteriosclerosis obliterans
  • No development reported Raynaud's disease; Thromboangiitis obliterans
  • Discontinued Spinal stenosis

Most Recent Events

  • 19 Mar 2025 Launched for Pulmonary arterial hypertension (In children) in Japan (PO)
  • 27 Dec 2024 Registered for Pulmonary arterial hypertension (In children) in Japan (PO)
  • 27 Dec 2024 Nippon Shinyaku receives label expansion for selexipag tablet (0.05 mg) for Pulmonary arterial hypertension (In children)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top